Spero Therapeutics Cash from Financing (TTM) Trends

Spero Therapeutics Inc (SPRO)

1.405 -0.06 (-4.42%) USD | NASDAQ | Apr 19, 16:00

1.40 0.00 (0.00%) After-Hours: 17:04

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2017. Upgrade now.

Date	Value
December 31, 2023	0.221M
September 30, 2023	14.40M
June 30, 2023	20.31M
March 31, 2023	-33.37M
December 31, 2022	-29.55M
September 30, 2022	6.617M
June 30, 2022	29.71M
March 31, 2022	83.56M
December 31, 2021	84.05M
September 30, 2021	49.79M
June 30, 2021	97.78M
March 31, 2021	105.00M
December 31, 2020	130.88M

Date	Value
September 30, 2020	120.39M
June 30, 2020	43.18M
March 31, 2020	44.76M
December 31, 2019	16.14M
September 30, 2019	10.36M
June 30, 2019	80.25M
March 31, 2019	71.09M
December 31, 2018	69.52M
September 30, 2018	144.38M
June 30, 2018	74.08M
March 31, 2018	73.11M
December 31, 2017	116.11M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-33.37M

Minimum

Mar 2023

130.88M

Maximum

Dec 2020

46.03M

Average

43.18M

Median

Jun 2020

Cash from Financing (TTM) Benchmarks